Listed by the USPTO as HASAN, KHALEDA B
Tech Center 1600 • Art Units: 1636
This examiner grants 60% of resolved cases
HASAN, KHALEDA B is assigned to tech center 1600 and art unit 1636. The profile includes 136 resolved cases, with an allowance rate of 59.6%, an interview lift of 49.3%, and a median of 1261 days to allowance.
Harbinger Health Inc., Intellia Therapeutics Inc., and Editas Medicine Inc. are the listed companies. The leading firms are GOODWIN PROCTER LLP, McNeill PLLC, and Clark+Elbing LLP - Moderna. The 49.3% interview lift is a prominent feature relative to the 59.6% allowance rate, supporting focused interview preparation. The 1261-day median should be included in prosecution scheduling.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17612807 | Methods Relating to Tuberculosis | Non-Final OA | The University of Nottingham |
| 18564572 | CAS13-BASED COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | King Abdullah University of Science and Technology |
| 18516247 | ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES | Non-Final OA | University of Miami |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.6% of resolved applications examined by Khaleda B Hasan were allowed (136 resolved cases), compared with 37.5% across Art Unit 1636 over the last five years.
This examiner's interview lift is +49.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Khaleda B Hasan took 1,261 days on average from filing to allowance.
Khaleda B Hasan examines applications in Art Unit 1636 in Tech Center 1600 (Biotechnology & Pharmaceuticals).